EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial

Michał Nowicki, Maciej Drożdż, Jarosław Wajda, Wiesław Klatko, Agnieszka Segiet-Święcicka

Nephron · 2024

DOI: 10.1159/000534070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephron, 2024. Verfasst von Michał Nowicki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódź, Łódź, Poland. Hauptthemen laut MEDLINE: Erythropoietin, Anemia, Renal Insufficiency, Chronic, Hematinics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renal anemia is one of the most common complications of chronic kidney disease (CKD). This real-life study assessed the effectiveness of methoxy polyethylene glycol-epoetin beta, a continuous erythropoietin receptor activator (C.E.R.A.), for the treatment of CKD-associated anemia in patients receiving dialysis in daily clinical practice.

Methods

247 patients receiving chronic intermitted dialysis in 26 centers in Poland with CKD-associated symptomatic anemia, ESA-naïve, and with balanced iron stores in the investigators’ opinion were enrolled this real-life study. Over 12 months, the following data were collected: hemoglobin (Hb) concentration and dosage, route of administration and dosing scheme of C.E.R.A., dialysis adequacy, adverse events, iron therapy, and blood transfusions.

Results

During the treatment, a Hb concentration of ≥10 g/dL was noted in 90.9% of hemodialysis patients (n = 224) and 96.0% of peritoneal dialysis patients (n = 23). At baseline, 7.8% of patients had a Hb concentration of 10–12 g/dL, which increased to 63.3% after 12 months. The median time when Hb concentration was maintained within 10–12 g/dL was 115.2 (interquartile range 49.1–188.7) days. A Hb concentration ≥12 g/dL was observed after 7 months of treatment in a maximum of 24.1% of hemodialysis patients, and 31.8% of peritoneal dialysis patients. The median time elapsed between the start of treatment and the first Hb concentration >10 g/dL was 42.0 (21.0–78.2) days. C.E.R.A. was well tolerated.

Conclusions

C.E.R.A. corrects CKD-associated anemia in dialysis patients, and maintains Hb levels within the recommended target range. The study also confirmed the acceptable safety profile of the drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErythropoietinAnemiaRenal Insufficiency, ChronicHematinicsPolyethylene GlycolsHumansHemoglobinsPolandRenal DialysisChronic DiseaseIron

Stichwörter der Autor:innen

Chronic kidney diseaseDialysisMethoxy polyethylene glycol-epoetin betaRenal anemia

Substanzen

continuous erythropoietin receptor activatorHemoglobinsErythropoietinIronHematinicsPolyethylene Glycols

Autor:innen und Institutionen

  • Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódź, Łódź, Poland.
  • DaVita Sp. z o.o., Wrocław, Poland.
  • Department of Internal Medicine with Nephrology Division, Specialistic Voivodeship Hospital, Rybnik, Poland.
  • Department of Nephrology, Specialistic Voivodeship Hospital, Ciechanów, Poland.
  • Institute of Education I.E., Warsaw, Poland.

Zitieren

APA

Nowicki, M., Drożdż, M., Wajda, J., Klatko, W., & Segiet-Święcicka, A. (2024). Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial. Nephron. https://doi.org/10.1159/000534070

Vancouver

Nowicki M, Drożdż M, Wajda J, Klatko W, Segiet-Święcicka A. Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial. Nephron. 2024. doi:10.1159/000534070

BibTeX
@article{Nowicki2024,
  author = {Nowicki, Michał and Drożdż, Maciej and Wajda, Jarosław and Klatko, Wiesław and Segiet-Święcicka, Agnieszka},
  title = {Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial},
  journal = {Nephron},
  year = {2024},
  doi = {10.1159/000534070}
}
Kostenlos starten →